222 related articles for article (PubMed ID: 35434110)
1. Treatment of
Wu HH; Fang SY; Chen YX; Feng LF
World J Clin Cases; 2022 Mar; 10(9):2743-2750. PubMed ID: 35434110
[TBL] [Abstract][Full Text] [Related]
2. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
[TBL] [Abstract][Full Text] [Related]
3. VV-ECMO combined with prone position ventilation in the treatment of Pneumocystis jirovecii pneumonia: A case report.
Jia L; Zhang Z; Bai Y; Du Q
Medicine (Baltimore); 2022 Jan; 101(1):e28482. PubMed ID: 35029898
[TBL] [Abstract][Full Text] [Related]
4. High initial (1, 3) Beta-d-Glucan concentration may be a predictor of satisfactory response of c aspofungin combined with TMP/SMZ for HIV-negative patients with moderate to severe Pneumocystis jirovecii pneumonia.
Jin F; Liu XH; Chen WC; Fan ZL; Wang HL
Int J Infect Dis; 2019 Nov; 88():141-148. PubMed ID: 31442630
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and diagnostic value of metagenomic next -generation sequencing in five cases of non-HIV related
Niu J; Wang J; Jia P; Zhang M; Wei E
Front Cell Infect Microbiol; 2023; 13():1132472. PubMed ID: 37009508
[TBL] [Abstract][Full Text] [Related]
6. Lessons from Multiple Infections Such as Lymphoma Complicated with Pneumocystis Infection: A Case Report.
Wang H; Lang Y; Cai X; Gao L; Yang S; Jin J
Infect Drug Resist; 2024; 17():1583-1588. PubMed ID: 38681899
[TBL] [Abstract][Full Text] [Related]
7. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
Dilworth TJ; Ibrahim OM; Mercier RC
J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
[TBL] [Abstract][Full Text] [Related]
8. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
[TBL] [Abstract][Full Text] [Related]
9. Single-center retrospective analysis of Pneumocystis jirovecii pneumonia in patients after deceased donor renal transplantation.
Zou J; Wang T; Qiu T; Zhou J; Chen Z; Ma X; Jin Z; Xu Y; Zhang L
Transpl Immunol; 2022 Jun; 72():101593. PubMed ID: 35367619
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
11. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
12. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
[TBL] [Abstract][Full Text] [Related]
13. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
[TBL] [Abstract][Full Text] [Related]
14. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
Awad M; Sierra CM; Mesghali E; Bahjri K
J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
[TBL] [Abstract][Full Text] [Related]
15. Clinical descriptive analysis of severe
Xie D; Xu W; You J; Yuan X; Li M; Bi X; Zhang K; Li H; Xian Y
Bioengineered; 2021 Dec; 12(1):1264-1272. PubMed ID: 33896387
[No Abstract] [Full Text] [Related]
16. Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy.
Shan W; Wang L; Qin J; Peng W; Ma K
Infect Drug Resist; 2024; 17():2299-2306. PubMed ID: 38868399
[TBL] [Abstract][Full Text] [Related]
17. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection.
Qi H; Dong D; Liu N; Xu Y; Qi M; Gu Q
BMC Infect Dis; 2023 Jun; 23(1):409. PubMed ID: 37328748
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis jirovecii Pneumonia in a Liver Transplant Recipient With an Adverse Reaction to Trimethoprim/Sulfamethoxazole Treated With a Sulfonamide Desensitization Protocol: Case Report.
Baran K; Furmańczyk-Zawiska A; Wieczorek-Godlewska R; Nitek P; Durlik M
Transplant Proc; 2024 May; 56(4):1000-1005. PubMed ID: 38760300
[TBL] [Abstract][Full Text] [Related]
20. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
